SenoRX, Inc.
SenoRx (NASDAQ: SENO) was founded in 1998 to design, develop, manufacture and market minimally invasive devices for the diagnosis and treatment of breast cancer. Since its founding, SenoRx has developed multiple, proprietary technology platforms and a unique product portfolio that address a range of diagnostic and therapeutic procedures. These products include the EnCor® vacuum-assisted breast biopsy system, compatible with ultrasound, stereotactic and MRI modalities, the Contura™ Multi-Lumen Balloon (MLB) – the only multi-lumen applicator for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer, and the SenoSonix II-t, which combines ultrasound and vacuum assisted biopsy in one system. It is the goal of SenoRx to become the leader in the breast care market by offering products that dramatically enhance patient outcomes. SenoRx has placed thousands of its products in breast centers, hospitals, outpatient centers, and radiation oncology centers across the United States and Canada, and around the world.
SenoRx’s field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 32 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is continuing development of additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information visit the company’s website at www.senorx.com
RELATED CONTENT
A potential paradigm shift is gathering momentum in the treatment of early-stage breast cancer, driven by data showing strong clinical outcomes for the use of more sophisticated therapies. Newer therapies using accelerated partial breast irradiation (APBI, also referred to as breast brachytherapy) not only allow women to remain whole, they also offer properly selected patients several advantages over traditional whole breast irradiation (WBI).
June 01, 2012 
May 5, 2010 - SenoRx Inc. announced it has entered into a definitive merger agreement with C. R. Bard at a price of $11 per share, or approximately $213 million in the aggregate.
May 05, 2010 
In the ongoing battle for breast conservation, the arguments in favor of brachytherapy, a form of radiotherapy where a radiation source is placed inside or next to the area requiring treatment, are compelling.
March 31, 2010 March 16, 2010 - SenoRx Inc. released a statement yesterday announcing with great sadness of its chairman and chief executive officer (CEO), Lloyd H. Malchow.
March 16, 2010 
October 21, 2009 - SenoRx today announced that it ranked among the fastest growing companies in Deloitte's 2009 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences and clean technology companies in North America.
October 21, 2009 
The versatility found throughout the EnCor breast biopsy product line extends into the MRI arena by offering grid and pillar/post compatibility in the same EnCor MRI product.
October 13, 2009 
SenoRx extends the EnCor breast biopsy product line into the MRI arena by offering grid and pillar/post compatibility in the same EnCor MRI product.
October 13, 2009 
October 13, 2009 - SenoRx extends the EnCor breast biopsy product line into the MRI arena by offering grid and pillar/post compatibility in the same EnCor MRI product.
October 13, 2009 
July 29, 2009 - SenoRx is featuring the Contura Multi-Lumen Balloon (MLB) Catheter for delivering brachytherapy to the surgical margins following lumpectomy for breast cancer in booth 762 at the AAPM 51st Annual Meeting that is taking place in Anaheim, Calif., from July 26-29. SenoRx representatives are demonstrating how Contura is a leader in MLB breast brachytherapy.
July 29, 2009 
May 26, 2009 - SenoRx will deliver three oral presentations summarizing clinical findings related to its Contura Multi-Lumen Balloon (MLB) Catheter at the American Brachytherapy Society (ABS) Annual Meeting being held May 31-June 2, 2009, in Toronto, Canada.
May 26, 2009